BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of $27.11 billion. The enterprise value is $8.75 billion.
Important Dates
The last earnings date was Monday, November 4, 2024, before market open.
| Earnings Date | Nov 4, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNTech SE has 239.74 million shares outstanding. The number of shares has decreased by -0.42% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 239.74M |
| Shares Change (YoY) | -0.42% |
| Shares Change (QoQ) | +1.73% |
| Owned by Insiders (%) | 18.41% |
| Owned by Institutions (%) | 20.13% |
| Float | 93.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.04 |
| Forward PS | 10.04 |
| PB Ratio | 1.27 |
| P/TBV Ratio | 1.36 |
| P/FCF Ratio | 21.33 |
| P/OCF Ratio | 15.97 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.58 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 6.88 |
Financial Position
The company has a current ratio of 7.33, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.33 |
| Quick Ratio | 7.10 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.21 |
| Interest Coverage | -24.21 |
Financial Efficiency
Return on equity (ROE) is -2.40% and return on invested capital (ROIC) is -1.40%.
| Return on Equity (ROE) | -2.40% |
| Return on Assets (ROA) | -1.23% |
| Return on Capital (ROIC) | -1.40% |
| Revenue Per Employee | $552,861 |
| Profits Per Employee | -$84,909 |
| Employee Count | 6,133 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 1.33 |
Taxes
In the past 12 months, BioNTech SE has paid $168.64 million in taxes.
| Income Tax | 168.64M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.97% in the last 52 weeks. The beta is 0.17, so BioNTech SE's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | +5.97% |
| 50-Day Moving Average | 113.25 |
| 200-Day Moving Average | 98.29 |
| Relative Strength Index (RSI) | 47.60 |
| Average Volume (20 Days) | 790,173 |
Short Selling Information
| Short Interest | 2.36M |
| Short Previous Month | 2.47M |
| Short % of Shares Out | 4.73% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.13 |
Income Statement
In the last 12 months, BioNTech SE had revenue of $3.39 billion and -$520.75 million in losses. Loss per share was -$2.16.
| Revenue | 3.39B |
| Gross Profit | 2.86B |
| Operating Income | -491.52M |
| Pretax Income | -269.98M |
| Net Income | -520.75M |
| EBITDA | -306.16M |
| EBIT | -491.52M |
| Loss Per Share | -$2.16 |
Full Income StatementBalance Sheet
The company has $18.64 billion in cash and $271.80 million in debt, giving a net cash position of $18.36 billion or $76.60 per share.
| Cash & Cash Equivalents | 18.64B |
| Total Debt | 271.80M |
| Net Cash | 18.36B |
| Net Cash Per Share | $76.60 |
| Equity (Book Value) | 21.32B |
| Book Value Per Share | 88.93 |
| Working Capital | 17.80B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.70 billion and capital expenditures -$338.61 million, giving a free cash flow of $1.27 billion.
| Operating Cash Flow | 1.70B |
| Capital Expenditures | -338.61M |
| Free Cash Flow | 1.27B |
| FCF Per Share | $5.30 |
Full Cash Flow StatementMargins
Gross margin is 84.31%, with operating and profit margins of -14.50% and -15.36%.
| Gross Margin | 84.31% |
| Operating Margin | -14.50% |
| Pretax Margin | -10.38% |
| Profit Margin | -15.36% |
| EBITDA Margin | -9.03% |
| EBIT Margin | -14.50% |
| FCF Margin | 37.48% |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.42% |
| Shareholder Yield | 0.42% |
| Earnings Yield | -1.92% |
| FCF Yield | 4.69% |
Dividend DetailsAnalyst Forecast
The average price target for BioNTech SE is $143.50, which is 26.90% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $143.50 |
| Price Target Difference | 26.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 3.91% |
| EPS Growth Forecast (5Y) | -9.22% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 5.93 and a Piotroski F-Score of 2.
| Altman Z-Score | 5.93 |
| Piotroski F-Score | 2 |